Pharma Flop: Eli Lilly's Alzheimer Cure Fails Drug Trials

Eli Lilly and Co.’s promising pharmaceutical drug for memory-fading disease, Alzheimer’s, has failed its large clinical trial. According to the company’s official statement, patients treated with solanezumab did not experience a statistically significant slowing in cognitive decline compared to patients treated with placebo.